Uncovering Promising Penny Stocks In September 2026

Over the last 7 days, the United States market has remained flat, though it is up 17% over the past year and earnings are expected to grow by 17% per annum in the coming years. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities, typically in smaller or newer companies. This article highlights three penny stocks that demonstrate financial strength and could offer compelling opportunities with less risk than one might expect.

Let's explore several standout options from the results in the screener.

Barinthus Biotherapeutics (BRNS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Barinthus Biotherapeutics plc, along with its subsidiaries, focuses on the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom, with a market cap of $28.47 million.

Operations: No revenue segments have been reported for Barinthus Biotherapeutics.

Market Cap: $28.47M

Barinthus Biotherapeutics is a pre-revenue company with a market cap of US$28.47 million, focusing on immunotherapies and vaccines. Despite its unprofitability, the company has managed to reduce losses from US$21.12 million to US$10.58 million year-over-year for the second quarter of 2026, indicating some improvement in financial management. However, its share price remains highly volatile and earnings are projected to decline by an average of 5.1% annually over the next three years. The firm is set for delisting from Nasdaq due to a merger scheme effective September 3, 2026, transitioning into Clywedog Therapeutics Holdings Inc., which will be listed under a new ticker symbol on Nasdaq.

• Jump into the full analysis health report here for a deeper understanding of Barinthus Biotherapeutics.
• Evaluate Barinthus Biotherapeutics' prospects by accessing our earnings growth report.

KORU Medical Systems (KRMD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the subcutaneous drug delivery market globally, with a market cap of $152.37 million.

Operations: The company generates revenue from its Surgical & Medical Equipment segment, amounting to $45.11 million.

Market Cap: $152.37M

KORU Medical Systems, with a market cap of US$152.37 million, has shown revenue growth, reporting US$12.05 million in Q2 2026 sales compared to US$10.19 million the previous year. Despite being unprofitable, it reduced its net loss over the past five years and maintains a strong cash position with no debt burden. The company's short-term assets exceed both its short- and long-term liabilities, providing financial stability. Recent amendments to company bylaws reflect governance adjustments without immediate impact on operations or strategy. Earnings guidance projects continued revenue growth for 2026 between US$47.5 million and US$48.5 million.

• Click here to discover the nuances of KORU Medical Systems with our detailed analytical financial health report.
• Assess KORU Medical Systems' future earnings estimates with our detailed growth reports.

WM Technology (MAPS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: WM Technology, Inc. operates as an online cannabis marketplace offering ecommerce and compliance software solutions to retailers and brands in the cannabis market both in the United States and internationally, with a market cap of $67.92 million.

Operations: The company's revenue is primarily generated from its Software & Programming segment, which accounts for $171.25 million.

Market Cap: $67.92M

WM Technology, Inc., with a market cap of US$67.92 million, faces challenges typical of penny stocks, including legal issues and fluctuating earnings. Despite a stable weekly volatility and being debt-free, the company reported a significant one-off loss impacting its recent financial results. Earnings growth has been negative over the past year; however, it remains profitable with net income increasing to US$2.02 million in Q2 2026 from US$1.43 million the previous year. The company anticipates a mid-single-digit revenue decline for Q3 2026 sequentially from Q2's US$42.45 million sales amid ongoing class action settlements potentially affecting investor sentiment.

• Take a closer look at WM Technology's potential here in our financial health report.
• Learn about WM Technology's future growth trajectory here.

Next Steps

• Get an in-depth perspective on all 317 US Penny Stocks by using our screener here.
• Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com